Humanin
Also known as: HN, mitochondrial-derived peptide
Humanin is a mitochondrial-derived peptide studied for reported cytoprotective and metabolic effects. It is a research peptide and is not approved for human use.
- Category
- Longevity / Mitochondrial
- Reported half-life
- Not well established
- Common forms
- Lyophilised powder for reconstitution, Research-grade solution
- Research status
- An active subject of ageing and cytoprotection research, mostly preclinical; not approved for human use in Australia. Human clinical data are limited.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in research to have cytoprotective (cell-protective) effects
- Studied for possible neuroprotective effects in laboratory models
- Reported to interact with apoptosis (programmed cell death) signalling
- Reported to be associated with metabolic and ageing-related pathways
How it is reported to work
Humanin is a small peptide encoded within the mitochondrial genome. It is proposed to act in a cytoprotective manner, reportedly interacting with apoptotic signalling proteins and certain cell-surface receptors to reduce cellular stress. These proposed mechanisms derive mainly from laboratory and animal studies and have not been established in humans.
Background
Humanin is a mitochondrial-derived peptide, one of a small group of peptides encoded by mitochondrial DNA. It is studied for its reported role in protecting cells from stress and in ageing-related biology. This page is educational information, not medical advice, and the effects below are reported claims, not established facts.
What the research shows
The bulk of Humanin research is preclinical, conducted in cell and animal models studying cytoprotection, neuroprotection and metabolism. These findings are preliminary and have not been confirmed in robust human clinical trials.
| Evidence type | Status |
|---|---|
| Cell / animal studies | Present |
| Robust human clinical trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, some people report interest in Humanin for “anti-ageing” and cellular protection. These are anecdotal reports without validated human outcomes. Reported benefits should not be read as proven, and nothing here is encouragement to use it.
Things to be aware of
Humanin is not approved for human use in Australia, and its long-term safety in people is not characterised. Grey-market preparations cannot be verified for purity or identity. If you have a health concern, the appropriate step is to consult a qualified healthcare professional. This article does not recommend obtaining or using Humanin.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported by users to be associated with a general sense of wellbeing
- Reported in research to have cytoprotective (cell-protective) effects
- Reported to be studied for neuroprotective effects in laboratory models
- Reported to be associated with metabolic and ageing-related pathways
- Reported to interact with apoptosis (programmed cell death) signalling
Common side effects
- Reported injection-site redness or irritation with reconstituted research material
- Reported mild fatigue or lethargy after dosing
- Reported transient headache
- Reported lightheadedness in some reported use
Rare / serious side effects
- Reported allergic or hypersensitivity reactions to unverified preparations
- Reported infection risk from non-sterile reconstitution and injection
- Unknown long-term effects, as no robust human safety data exists
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Humanin. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-injection of unregulated grey-market powder of unverified purity or identity
- Reported prolonged or high-dose use based on unproven cytoprotective and longevity claims
- Reported sharing or reusing needles when self-administering research material
- Reported substitution of medical care with this unapproved peptide for serious conditions
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Users report only subtle, subjective changes over weeks, with cytoprotective and longevity claims unproven in humans.
First effects
Some report subtle wellbeing changes within the first weeks
Noticeable change
Reported subjective changes over the first month of reported use
Clear results
Any reported wellbeing changes described over several weeks to months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Humanin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous (SubQ) injection |
|---|---|
| Typical reported dose | Reported at roughly 1–5 mg, though dosing is not well established |
| Frequency | Reported anywhere from a few times per week to daily; no standard schedule exists |
| Cycle length | Not well established; reported use varies widely |
Reported reconstitution (mg → units)
Example only: a 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 5 mg dose is about 1 mL (100 units on a U-100 syringe); a 1 mg dose is about 0.2 mL (20 units).
Work out the units for your vial → CalculatorReported use is commonly described as cycles of several weeks of daily dosing followed by a break. This is reported information about patterns of use, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
Humanin is not approved for human use in Australia and has limited human safety data. Its long-term effects in people are not characterised, and grey-market preparations cannot be verified for purity or identity. Anyone with a health concern should consult a qualified healthcare professional rather than self-experiment.